Meeting News Coverage

Micro-stent combined with phaco reduces IOP, medication use at 3 years

FORT LAUDERDALE, Fla. — A supraciliary micro-stent reduced IOP with a high safety profile in patients with open-angle glaucoma, according to a scientific poster presented at the American Glaucoma Society meeting here.

Reay H. Brown, MD, and colleagues reported results of the CyPass Clinical Experience study, a prospective, multicenter analysis that included 522 patients; 269 patients underwent combined small-incision cataract surgery and implantation of a CyPass micro-stent (Transcend Medical). Of the 269 patients who had combined surgery, 102 had uncontrolled IOP (21 mm Hg or higher) and 167 had controlled IOP (lower than 21 mm Hg).

Mean baseline IOP was 19.8 mm Hg in the overall combined surgery group, 25.4 mm Hg in the uncontrolled IOP cohort and 16.5 mm Hg in the controlled IOP cohort.

Average baseline number of medications was 2.1 in the overall group, 2 in the uncontrolled IOP cohort and 2.1 in the controlled IOP cohort.

Among the 169 patients in the combined surgery group available for evaluation at 36 months, mean IOP was 16.5 mm Hg and mean number of medications was 1.3.

In the uncontrolled IOP cohort, mean IOP was 17.1 mm Hg, a decrease of 29%, at 3 years. IOP control was maintained and medication use was reduced 50% in the controlled IOP cohort at 3 years.

No major sight-threatening adverse events were reported.

“The safety profile is comparable to other minimally invasive glaucoma surgery procedures,” Brown and colleagues wrote. – by Matt Hasson and Patricia Nale, ELS

Disclosure: Brown reports he has a patent with or receives royalties from Glaukos and Rhein and is a consultant for Ivantis and Transcend.

FORT LAUDERDALE, Fla. — A supraciliary micro-stent reduced IOP with a high safety profile in patients with open-angle glaucoma, according to a scientific poster presented at the American Glaucoma Society meeting here.

Reay H. Brown, MD, and colleagues reported results of the CyPass Clinical Experience study, a prospective, multicenter analysis that included 522 patients; 269 patients underwent combined small-incision cataract surgery and implantation of a CyPass micro-stent (Transcend Medical). Of the 269 patients who had combined surgery, 102 had uncontrolled IOP (21 mm Hg or higher) and 167 had controlled IOP (lower than 21 mm Hg).

Mean baseline IOP was 19.8 mm Hg in the overall combined surgery group, 25.4 mm Hg in the uncontrolled IOP cohort and 16.5 mm Hg in the controlled IOP cohort.

Average baseline number of medications was 2.1 in the overall group, 2 in the uncontrolled IOP cohort and 2.1 in the controlled IOP cohort.

Among the 169 patients in the combined surgery group available for evaluation at 36 months, mean IOP was 16.5 mm Hg and mean number of medications was 1.3.

In the uncontrolled IOP cohort, mean IOP was 17.1 mm Hg, a decrease of 29%, at 3 years. IOP control was maintained and medication use was reduced 50% in the controlled IOP cohort at 3 years.

No major sight-threatening adverse events were reported.

“The safety profile is comparable to other minimally invasive glaucoma surgery procedures,” Brown and colleagues wrote. – by Matt Hasson and Patricia Nale, ELS

Disclosure: Brown reports he has a patent with or receives royalties from Glaukos and Rhein and is a consultant for Ivantis and Transcend.

    See more from American Glaucoma Society Meeting